Vancouver, British Columbia--(Newsfile Corp. - February 13, 2018) - CVR Medical Corp. (TSXV: CVM) (FSE: B3BN) (OTCQB: CRRVF) ("CVR Medical") announces placement of two additional wireless Carotid Stenotic Scan (CSS) devices into clinical trials at historic Methodist Hospital, part of the Thomas Jefferson University Hospital System. This deployment will be combined with the three wireless CSS devices already in use across the Thomas Jefferson University Hospital footprint. This critical milestone will assist in increasing the volume of clinical substantiation data to be used in the upcoming FDA submission to acquire market clearance.
The historic Methodist Hospital campus is located in the heart of south Philadelphia, having provided care since its doors opened in 1892. Over a century later, it now stands as a landmark of the Philadelphia landscape, boasting a bed count of over two hundred. In 1996, Methodist Hospital became a division of Thomas Jefferson University Hospital.
"When entering Methodist Hospital one cannot help but feel as though they are walking into a part of history," states CVR COO Tony Robinson. "From its inception in the late 1800's, to the support of world war II troops, to the renowned nursing school once located on the premise; I like to think we are adding to this line of accomplishment in bringing the trial to the Methodist site. I hope looking back, the CSS is another feather in the hat of the historic locale."
For additional information on the organization, leadership, and current news, please visit the company's website www.CVRMed.com.
About CVR Medical
CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the "Joint Venture"). The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.
ON BEHALF OF THE BOARD:
(signed) "Peter Bakema"
CEO, President & Director
For further information contact:
Peter Bakema, CEO, President and Director
Telephone: (734) 718-5115
Email: info@cvrmed.com
or
Brisco Capital Partners Corp.
Scott Koyich, President
Telephone: (403) 262-9888
This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to the Joint Venture. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management's current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the Joint Venture, (5) the risk that the Company or the Joint Venture does not execute its business plan, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company's control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.
THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
